(Law360) The California Supreme Court will hear oral arguments next month in a proposed class action brought by purchasers of antibiotic Cipro alleging Bayer Corp. illegally paid several generics makers nearly $400 million to delay market entry, and experts say a ruling that subjects pay-for-delay settlements to a stricter standard of review could reverberate nationwide, deterring drug companies from entering into these pacts.
News
02.11.2015